Spinal muscular atrophy (SMA) is a rare, genetic condition that, across all types, affects ~1,600 people in the UK.1 It can cause muscle weakness which gets worse over time, causing movement, ...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA ...

The local unit of US biotech major Biogen today announced that the UK’s Medicines and Healthcare Products Regulatory Agency ...

This high dose nusinersen regimen for spinal muscular atrophy includes 50 mg loading doses and 28mg maintenance doses.

Biogen Inc. BIIB shares are up on Monday following the FDA’s approval of a new high-dose regimen for Spinraza (nusinersen), a ...

BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...

The MarketWatch News Department was not involved in the creation of this content. SCHAUMBURG, Ill., March 30, 2026 /PRNewswire/ -- Cure SMA, the leading nonprofit organization supporting those ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm. The ...

Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 ⁠billion in cash, expanding its portfolio of rare-disease medicines, the companies said on Tuesday. The deal marks Biogen's push to ...

Biogen BIIB0.89%increase; green up pointing triangle agreed to acquire Apellis Pharmaceuticals APLS 0.01%increase; green up pointing triangle for approximately $5.6 billion, expanding its portfolio in ...